Recent ALGS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:05:59 PM
- Aligos Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 08/15/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:09:21 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:08:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:11:01 PM
- Aligos Therapeutics Strengthens Board with Two New Independent Directors • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:14:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:05:31 PM
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 • GlobeNewswire Inc. • 07/30/2024 08:05:00 PM
- Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. • GlobeNewswire Inc. • 07/22/2024 01:00:00 PM
- Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:56 PM
- Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 • GlobeNewswire Inc. • 05/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:02:52 PM
- Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH • GlobeNewswire Inc. • 05/21/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:05:32 PM
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 08:05:00 PM
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
FEATURED ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM